← All countries · South-East Asia
98%
MCV1
2025 · WHO/UNICEF estimate
95%
DTP3
2025 · WHO/UNICEF estimate
95%
IPV complete
2025 · WHO/UNICEF estimate
95%
HepB3
2025 · WHO/UNICEF estimate
17,995
Measles cases
2025 reported
2,149
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 91%2025 · WHO/UNICEF estimate | 91.1% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 97%2025 · WHO/UNICEF estimate | 96.8% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 95%2025 · WHO/UNICEF estimate | 94.6% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 95%2025 · WHO/UNICEF estimate | 92.0% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 95%2025 · WHO/UNICEF estimate | 94.9% | C · weak | |
| MCV1First dose of measles-containing vaccine | 98%2025 · WHO/UNICEF estimate | 98.3% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 94.7% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 98%2025 · WHO/UNICEF estimate | 98.3% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 95%2025 · WHO/UNICEF estimate | 94.6% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 70%2025 · WHO/UNICEF estimate | 92.0% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 95%2025 · WHO/UNICEF estimate | 94.6% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 95.7%2025 · Administrative (country-reported) | 95.7% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 97%2025 · WHO/UNICEF estimate | 96.5% | D · poor | |
| RotaCRotavirus vaccine, complete series | 91%2025 · WHO/UNICEF estimate | 90.7% | B · good | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 96.8%2025 · Administrative (country-reported) | 96.8% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 93%2024 · WHO/UNICEF estimate | — | C · weak |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 17,9952025 | 12.3per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 2,8132025 | 1.9per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 722025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 3392025 | 0.2per 1,000,000 total population | C · weak | |
| Pertussis (whooping cough) all countries · vaccine evidence | 2,1492025 | 1.5per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 3,2492025 | 2.2per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 382025 | 0per 1,000,000 total population | A · strong | |
| Neonatal tetanus all countries · vaccine evidence | 382025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02001 | 0per 1,000,000 total population | too few points | no data |
| Japanese encephalitis all countries · vaccine evidence | 1,4142025 | 1per 1,000,000 total population | B · good | |
| Invasive meningococcal disease all countries · vaccine evidence | 772025 | 0.1per 1,000,000 total population | too few points | D · poor |
| Typhoid all countries · vaccine evidence | 568,0882025 | 388.1per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (38 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | 0-1 year |
| DTWPDTwP (Whole cell) vaccine | 4 | M16-M24 | General/routine | 1.5 months-7 years |
| DTWPDTwP (Whole cell) vaccine | 5 | Y5-Y6 | General/routine | 1.5 months-7 years |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | W6 | General/routine | up to 1 year |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | W10 | General/routine | up to 1 year |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | W14 | General/routine | up to 1 year |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | |
| IPV_FRACIPVf (Inactivated polio vaccine fractional dose) | 1 | W6 | General/routine | fractional dose |
| IPV_FRACIPVf (Inactivated polio vaccine fractional dose) | 2 | W14 | General/routine | fractional dose |
| IPV_FRACIPVf (Inactivated polio vaccine fractional dose) | 3 | M9 | General/routine | fractional dose |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 1 | M9-M12 | General/routine · SUBNATIONAL | 9 months - 2 years (JE vaccine is given in the National Immunization schedule from 9 months to 2 years. The JE vaccination is given in campaign mode before introduction in routine immunization, in identified districts. This campaign is done in target group of 1-15 years) |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 2 | M16-M24 | General/routine · SUBNATIONAL | 9 months - 2 years (JE vaccine is given in the National Immunization schedule from 9 months to 2 years. The JE vaccination is given in campaign mode before introduction in routine immunization, in identified districts. This campaign is done in target group of 1-15 years) |
| MRMR (Measles and rubella) vaccine | 1 | M9-M12 | General/routine | 0-5 years |
| MRMR (Measles and rubella) vaccine | 2 | M16-M24 | General/routine | 0-5 years |
| OPVOPV (Oral polio vaccine) | 1 | B | General/routine | 0-5 years |
| OPVOPV (Oral polio vaccine) | 2 | W6 | General/routine | 0-5 years |
| OPVOPV (Oral polio vaccine) | 3 | W10 | General/routine | 0-5 years |
| OPVOPV (Oral polio vaccine) | 4 | W14 | General/routine | 0-5 years |
| OPVOPV (Oral polio vaccine) | 5 | M16-M24 | General/routine | 0-5 years |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | W6 | General/routine | up to 1 year |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | W14 | General/routine | up to 1 year |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M9 | General/routine | up to 1 year |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | W6 | General/routine | up to 1 year, both RV1 and RV5 administered |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | W10 | General/routine | up to 1 year, both RV1 and RV5 administered |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 3 | W14 | General/routine | up to 1 year, both RV1 and RV5 administered |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | W6 | General/routine | up to 1 year, both RV1 and RV5 administered |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | W10 | General/routine | up to 1 year, both RV1 and RV5 administered |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | W14 | General/routine | up to 1 year, both RV1 and RV5 administered |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | Pregnant women 2nd dose of Td vaccine is administered after 4 weeks of 1st dose, at least 4 weeks before delivery |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +W4 | Pregnant women | Pregnant women 2nd dose of Td vaccine is administered after 4 weeks of 1st dose, at least 4 weeks before delivery |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 6 | Y10 | General/routine | 10Y, 16Y, and 2 Td doses for pregnant women |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 7 | Y16 | General/routine | 10Y, 16Y, and 2 Td doses for pregnant women |
| VITAMINAVitamin A supplements | 1 | M9 | General/routine | 0-5 years |
| VITAMINAVitamin A supplements | 2 | M18 | General/routine | 0-5 years |
| VITAMINAVitamin A supplements | 3 | M24 | General/routine | 0-5 years |
| VITAMINAVitamin A supplements | 4 | M30 | General/routine | 0-5 years |
| VITAMINAVitamin A supplements | 5 | M36 | General/routine | 0-5 years |
| VITAMINAVitamin A supplements | 6 | M42 | General/routine | 0-5 years |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.